Explore Supplements Subscribe
The VerdictLOW CONVICTIONVerdict Score 79Worth-It: Situational ROI (62/100)

For most healthy adults under 75, routine vitamin D supplementation does nothing — but it becomes genuinely essential once you're confirmed deficient (serum <20 ng/mL) or over 75.

That's the general answer. Your stack is different.

Check your whole stack
SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.
Vitamin D hero
Vitamins & Minerals · Supplement Engine

Vitamin D

Cholecalciferol / Ergocalciferol

Conditional

Triage: RED  ·  2026-03-19 PM  ·  The Verdict

§2 — Quick Answer

Billions spend it. Most don't need it.

Vitamin D is the most universally recommended supplement in health culture — and one of the most thoroughly debunked for healthy adults under 75. Four mega-RCTs enrolling over 70,000 people found zero benefit for fractures, cancer, cardiovascular disease, falls, or depression in unselected adults.

The catch: for people who are actually deficient (serum 25(OH)D below 20 ng/mL), or over 75, supplementation is genuinely evidence-backed. The problem is most people who take it aren't in either category — they're just fixing a number on a blood test that didn't need fixing.

Don't supplement blind. Test first. If you're above 20 ng/mL and under 75, the £8 bottle is doing nothing except improving the supplement industry's margins.

§3 — What People Claim

The pitch that sold a billion bottles

Vitamin D claims

The narrative is compelling: modern life keeps us indoors, billions are deficient, and this hidden deficiency silently drives nearly every chronic disease. The Endocrine Society's 2011 guidelines supercharged this idea by labelling anything under 30 ng/mL as "insufficient" — moving the goalposts from a narrow clinical definition to a population-wide deficiency epidemic.

"Get your vitamin D levels tested — low D causes fractures, cancer, heart disease, depression, low testosterone, and weakened immunity. Everyone needs to supplement."
"Athletes need it for testosterone, muscle power, and recovery. Over-50s need it to prevent falls and fractures. Desk workers are silently degrading every metabolic process."

At £8-15 per bottle, it became one of the cheapest "insurance policies" in the supplement stack. The observational epidemiology seemed to confirm everything: people with low 25(OH)D had dramatically higher rates of almost every chronic disease. It looked like a slam-dunk. It wasn't.

§4 — What the Evidence Shows

Thirty years of observational promise. Zero RCT payoff.

Evidence review
Claimed Benefit Verdict Key Evidence
Fracture prevention DEBUNKED HR 0.98 (p=0.70). VITAL, N=25,871. USPSTF Grade D against.
Fall prevention (60+) DEBUNKED DO-HEALTH, N=2,157. No effect. USPSTF Grade D against.
Cancer prevention DEBUNKED VITAL + D-HEALTH, N=21,315+. HR ~1.0. Null.
Cardiovascular outcomes DEBUNKED VITAL + ViDA, N=30,000+. Null across endpoints.
Depression prevention DEBUNKED VITAL-DEP, N=18,353. 2,000 IU/day over 5+ years. No difference.
Muscle function/strength (replete) DEBUNKED DO-HEALTH + VITAL, N=27,000+. No improvement in grip strength or function.
Testosterone (normal levels) DEBUNKED Lerchbaum 2017, N=98. +0.5 nmol/L (p=0.497). Null.
Athletic performance INSUFFICIENT Meta-analyses: null in replete athletes. No RCT evidence for supraphysiological benefit.
Bone health (confirmed deficient) STRONG Prevents osteomalacia + corrects secondary hyperparathyroidism. IOM + ES 2024.
Respiratory infections MODERATE Benefit in children, adolescents, severely deficient adults. ES 2024.
Mortality reduction (≥75) MODERATE Signal in meta-analyses. ES 2024 recommends empiric supplementation ≥75.
Pre-eclampsia (pregnancy) MODERATE Reduced risk. Endocrine Society 2024.
Prediabetes risk reduction EMERGING ~3,500 IU/day signal for high-risk prediabetics. ES 2024.

Key Takeaways

Routine supplementation in unselected adults under 75 has zero proven benefit for any major endpoint. STRONG

What would change this: A mega-RCT enrolling only confirmed severely deficient adults (<12 ng/mL) with hard endpoints over 3 years.

2024 Endocrine Society and USPSTF explicitly recommend against routine 25(OH)D screening or high-dose supplementation in healthy adults <75. STRONG

What would change this: Updated guidelines based on new RCT evidence in deficient populations specifically.

Benefit is real and clinically meaningful when correcting confirmed deficiency (<20 ng/mL) — the mechanism works; most supplemented adults just aren't deficient. STRONG

What would change this: Evidence showing serum 25(OH)D above 20 ng/mL provides additional benefit for skeletal or immune outcomes.

Magnesium is an obligate cofactor for every enzymatic step — high-dose D without adequate magnesium causes functional resistance. MODERATE

What would change this: RCTs comparing D3 alone vs D3 + magnesium with serum 1,25(OH)2D and clinical endpoints.

What definitely doesn't work

  • Fracture prevention in healthy adults — VITAL's N=25,871 study: HR 0.98, p=0.70. Literal null result.
  • Vitamin D for depression — VITAL-DEP (N=18,353): no reduction in late-life depression over 5+ years at 2,000 IU/day.
  • Testosterone or muscle performance in replete men — Median TT change: +0.5 nmol/L, p=0.497. Not a rounding error — genuinely null.
  • The "optimal level is 30-50 ng/mL" doctrine — The 2011 ES threshold was based on PTH suppression. Both IOM and 2024 ES confirm 20 ng/mL is sufficient for hard outcomes.
  • Routine 25(OH)D screening in healthy adults <75 — Explicitly NOT recommended by USPSTF 2024 or ES 2024.
§5 — How It Works

A pro-hormone, not a vitamin — and the mechanism matters

Vitamin D mechanism

Vitamin D isn't technically a vitamin. It's a secosteroid pro-hormone — a precursor that must be chemically activated twice before it does anything biologically useful. This two-step process is where most of the nuance lives.

Step 1 — Liver (Hepatic Hydroxylation)

D3 (from skin or supplements) is hydroxylated by the enzyme CYP2R1 into 25-hydroxyvitamin D [25(OH)D] — the circulating biomarker measured on blood tests. Magnesium is required at this step. This step is entirely bypassed if you take calcifediol (pre-hydroxylated D3) directly.

Step 2 — Kidneys (Renal 1α-Hydroxylation)

25(OH)D is converted by CYP27B1 into calcitriol [1,25(OH)2D] — the biologically active hormone. Magnesium required again. This step is tightly regulated by parathyroid hormone (PTH) and feedback inhibition — which is why high-dose supplementation hits diminishing returns once levels reach sufficiency.

Genomic Action — 900+ Genes

Calcitriol binds the intracellular Vitamin D Receptor (VDR), forms a heterodimer with RXR, and translocates to the nucleus. It regulates expression of over 900 genes governing calcium homeostasis, immune function, and cell cycle. This is why severe deficiency causes rickets (bone mineralisation failure), myopathy (VDR is expressed in skeletal muscle), and immune dysregulation.

Why the observational promise collapsed

Low serum 25(OH)D is heavily confounded. Sick, sedentary, and obese people go outside less. Obesity causes fat-soluble vitamin D to sequester in expanded adipose tissue, diluting serum levels. Chronic inflammation downregulates the entire vitamin D pathway. Low 25(OH)D is a biomarker of ill health, not its cause. Correcting the number in someone who isn't truly deficient doesn't reverse the underlying disease — it just satisfies the blood test.

§6 — The Debate

Where studies disagree

Debate 1: Observational signal vs RCT null

Hundreds of cohort studies
Low 25(OH)D strongly predicts cancer, CVD, fractures, and mortality. The associations are large, consistent, and dose-responsive.
VS
VITAL + ViDA + D-HEALTH + DO-HEALTH
Supplementation provides zero risk reduction for any of these endpoints in general adults. Four independent mega-RCTs, same result.
Direction: Reverse causation. Sick, sedentary, obese people generate less sun-derived D. Low D is a biomarker of ill health, not its cause. The correlation was real; the causal arrow was backwards.

Debate 2: The "30 ng/mL threshold" war

Endocrine Society 2011 Guidelines
Insufficiency begins at <30 ng/mL. Optimal is 30-100 ng/mL. Most adults need 1,500-2,000 IU/day to reach this level.
VS
IOM + Endocrine Society 2024
20 ng/mL meets skeletal needs for 97.5% of people. Explicitly recommends against routine screening or empiric supplementation >600-800 IU in healthy adults <75.
Direction: Original guidelines relied on physiological proxy markers (PTH suppression). Updated guidelines require hard clinical endpoints (fractures, mortality) from mega-RCTs — all null. Science moved. The guidelines caught up.

Debate 3: VDR muscle biology vs clinical null

In vitro + muscle biopsy studies
VDR is expressed in skeletal muscle. Knockout models develop myopathy. The mechanism for muscle benefit exists at the cellular level.
VS
VITAL + DO-HEALTH
2,000 IU/day D3 did not improve grip strength, physical performance, or fall prevention in adults ≥50. N=27,000+.
Direction: Threshold effect. The mechanism is real but requires reversing severe deficiency. Pushing from 25 ng/mL to 40 ng/mL in a replete adult provides zero additive benefit. The mechanism exists at the floor, not the ceiling.

Current consensus: The null-results verdict from mega-RCTs is now enshrined in 2024 guidelines from both the Endocrine Society and USPSTF. The observational era is over. The question has shifted from "does it work?" to "for whom specifically?"

§7 — Real World vs Lab

What the trials couldn't tell you

Limitation 1: Most RCTs enrolled replete adults

Lab Finding VITAL enrolled adults with mean 25(OH)D of 25-30 ng/mL. These trials were designed to test sufficiency-to-optimality — structurally incapable of detecting benefit in truly deficient populations.
Real World Confirmed deficient populations (<20 ng/mL) remain under-studied and likely still benefit. But this is a much smaller group than marketing suggests.
MORE CONSERVATIVE

Limitation 2: Obesity destroys standard dosing

Lab Finding Standard 2,000 IU doses reliably raise 25(OH)D in lean adults in clinical trials.
Real World In obese individuals (BMI ≥30), D3 distributes volumetrically into the expanded adipose compartment, blunting the serum response. A 2-3× dose escalation or calcifediol is required to achieve equivalent serum levels.
MORE CONSERVATIVE

Limitation 3: Supplement quality varies wildly

Lab Finding RCTs use verified pharmaceutical-grade doses with tight quality control.
Real World OTC vitamin D supplement labelling accuracy varies ±30-50% in consumer products. An "800 IU" capsule may deliver 500-1,100 IU depending on the brand.
LESS RELIABLE
§8 — The Protocol

Dosing that actually matches the evidence

Protocol and dosing
Population Dose Form Loading? Source
Healthy adults <75, not deficient 600-800 IU/day D3 No IOM RDA + ES 2024
Adults ≥75 800 IU/day D3 (or calcifediol if malabsorption) No ES 2024
Confirmed deficient (<20 ng/mL) 2,000-6,000 IU/day D3 50,000 IU/week × 8 weeks ES 2024
Obese (BMI ≥30) + deficient 2-3× standard, or calcifediol Calcifediol (preferred) Calcifediol loading ES 2024
Pregnant women 600-5,000 IU/day D3 No ES 2024
High-risk prediabetics ~3,500 IU/day D3 No ES 2024
Children 1-18 600-1,000 IU/day D3 No ES 2024 + IOM

Forms Comparison

D3 (Cholecalciferol)
Baseline (100%)
General supplementation — requires bile acids + chylomicrons. Fat sequestration at high BMI.
£5-10/month
Calcifediol (25-OH D3)
300-600% of D3
Obese, GI malabsorption, hepatic dysfunction. Hydrophilic — portal vein direct absorption, bypasses hepatic hydroxylation.
£15-30/month
D2 (Ergocalciferol)
~53% of D3
Plant-based necessity only. Shorter half-life, 2-3× less storage — avoid unless vegan requirement.
£5-10/month
Calcitriol (1,25-OH D3)
Active hormone (Rx)
Renal failure, hypoparathyroidism only. No self-regulation feedback — toxicity risk without medical supervision.
Prescription only

Absorption Tips

🍳
Always take with a fat-containing meal D3 and D2 are fat-soluble. Co-ingestion with dietary fat increases absorption 32-50%. Don't take on an empty stomach.
💎
Magnesium is non-negotiable above 1,000 IU/day Every enzymatic step — hepatic hydroxylation, renal 1α-hydroxylation, VDR binding — requires magnesium. High-dose D without magnesium creates functional resistance and actively depletes systemic magnesium. Target 300-420 mg/day from diet + supplement (glycinate or malate preferred).
⚠️
Calcium caution — don't combine casually WHI trial: combined Ca + 400 IU D3 increased kidney stone incidence by 17%. Avoid the combination unless clinically directed.
🏋️
Obese or malabsorptive: don't use standard D3 Volumetric dilution into expanded adipose tissue means standard 800-2,000 IU OTC doses may fail to raise serum levels. Calcifediol bypasses this entirely — it's hydrophilic and absorbs via portal vein.
§9 — Safety & Interactions

The interactions that actually matter

Safety

Digoxin (Lanoxin) SEVERE

D-induced hypercalcemia shortens ventricular refractory period → digoxin toxicity + fatal arrhythmia risk. Strict calcium monitoring. Avoid high-dose vitamin D if on digoxin without cardiology supervision.

Thiazide Diuretics (hydrochlorothiazide) HIGH

Thiazides reduce renal calcium excretion; high-dose D increases intestinal calcium absorption → severe hypercalcemia risk. Monitor serum calcium; avoid high-dose combination.

Magnesium Depletion HIGH

High-dose D actively depletes systemic magnesium at all hydroxylation steps. Co-supplement magnesium at ≥300 mg/day when taking >1,000 IU D3 daily.

Statins (atorvastatin, simvastatin) MODERATE

Vitamin D induces CYP3A4, increasing statin clearance; paradoxically may also enhance LDL reduction via separate lipid pathway. Monitor lipid panel — generally manageable.

Orlistat / Bile Acid Sequestrants MODERATE

Reduces fat-soluble vitamin absorption. Separate dosing by 2+ hours; consider calcifediol in persistent cases.

Corticosteroids MODERATE

Impair vitamin D metabolism and reduce calcium absorption → accelerated glucocorticoid-induced osteoporosis. Require higher D3 dose on long-term corticosteroid therapy.

Calcium Supplements (combined) MODERATE

WHI: Ca + 400 IU D3 → 17% increased kidney stone incidence. Avoid unsupervised high-dose calcium + D3 combination.

Contraindicated Populations

Do NOT supplement without medical supervision:

  • Sarcoidosis, tuberculosis, granulomatous diseases — Ectopic CYP27B1 in macrophages produces unregulated 1,25(OH)2D → extreme hypercalcemia risk with ANY supplementation.
  • Williams Syndrome — Genetic hypersensitivity to vitamin D → hypercalcemia.
  • Primary Hyperparathyroidism — Can exacerbate hypercalcemia; requires endocrinology input (may paradoxically also be deficient).

Upper Limits

IOM Tolerable Upper Intake Level: 4,000 IU/day (adults) — conservative, based on long-term hypercalcemia risk.

Endocrine Society clinical threshold: No toxicity typically observed below 10,000 IU/day short-term — used for supervised correction loading (50,000 IU/week × 8 weeks).

Clinical toxicity threshold: Hypercalcemia typically requires sustained serum 25(OH)D >150 ng/mL (>375 nmol/L).

§10 — The Nuance

Who it's actually for

Population nuance

Who Benefits

  • Confirmed deficient (<20 ng/mL) — HIGH conviction. Dramatic effect reversing real pathology.
  • Adults ≥75 — MODERATE. ES 2024 empiric recommendation based on mortality signal.
  • Children & adolescents (1-18) — MODERATE. Reduces respiratory infections. Established for rickets prevention.
  • Pregnant women — MODERATE. Reduces pre-eclampsia risk.
  • Obese + confirmed deficient — HIGH conviction on mechanism; calcifediol required for absorption.
  • High-risk prediabetics — EMERGING. ~3,500 IU/day signal for reduced diabetes conversion.

Cost-Effectiveness

For D3: £5-10/month if justified. Food alternative: 15-20 min midday sun (spring-autumn, arms/face exposed) = 10,000-20,000 IU/day synthesised from UVB. Oily fish 100g salmon ≈ 600-1,000 IU. For the general population: optimise sunlight first, test before supplementing. For obese or malabsorptive clients: calcifediol at £15-30/month is justified — food-first is insufficient.

Quick Reference

Verdict
CONDITIONAL — confirmed deficient or ≥75 only
Best Form
D3 (cholecalciferol); calcifediol for obese/malabsorptive
Dose
600-800 IU maintenance; 50,000 IU/week × 8 weeks for deficiency correction
Timing
Always with a fat-containing meal
Key Cofactor
Magnesium ≥300 mg/day when >1,000 IU/day
Key Interaction
Digoxin (SEVERE); thiazides (HIGH); magnesium depletion (HIGH)
Cost
£5-10/month D3; £15-30 calcifediol
Food Alternative
15-20 min midday sun (spring-autumn); oily fish 2-3×/week
§11 — Conviction

Where the evidence lands

Dual conviction — the answer depends entirely on who you're asking about

LOW — General Population HIGH — Confirmed Deficient / ≥75

Four mega-RCTs totalling 70,000+ participants. Two independent 2024 guidelines both landing in the same place. This is one of the most robustly-tested null results in nutritional medicine for healthy adults — and one of the most clearly beneficial interventions when the clinical indication actually exists.

What would change this conviction

A trial enrolling only confirmed severely deficient adults (<12 ng/mL), stratified by age, BMI, and baseline magnesium status, testing D3 alone vs D3 + magnesium vs calcifediol with hard endpoints (falls, fractures, sarcopenia, mortality) over 3 years.

Current mega-RCTs (VITAL mean baseline 30 ng/mL) were structurally incapable of detecting benefit in deficient populations. The trial hasn't been done in the population it would actually matter for. This trial would either confirm targeted benefit — or close the hypothesis entirely.

For the LOW conviction on general population: nothing plausible would change this. The null result has been replicated too many times across too many endpoints with too many independent research groups.

§12 — Sources

The evidence base

LeBoff et al. (2022)N=25,871
Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. NEJM. No reduction in total, hip, or nonvertebral fractures.
Waterhouse et al. (2022)N=21,315
Effect of monthly high-dose vitamin D supplementation on chronic disease in older adults (D-HEALTH). Lancet Diabetes & Endocrinology. All-cause mortality HR 1.04 (ns).
Scragg et al. (2017)N=5,110
Monthly High-Dose Vitamin D Supplementation and Cancer Risk (ViDA). J Steroid Biochem Mol Biol. Null for CVD, falls, and fractures.
Bischoff-Ferrari et al. (2020)N=2,157
DO-HEALTH: 2,000 IU/day Vitamin D3 + Omega-3 + Exercise in Adults ≥70. JAMA. Null for falls, frailty, and functional decline for D3 alone.
Okereke et al. (2020)N=18,353
Effect of Vitamin D3 Supplementation on Late-Life Depression (VITAL-DEP). JAMA. No reduction in depression over 5+ years at 2,000 IU/day.
Endocrine Society Clinical Practice Guideline (2024)
Vitamin D for the Prevention of Disease. Recommends against routine screening and high-dose supplementation in healthy adults <75. First-line recommendation for ≥75 and confirmed deficient.
USPSTF (2024 draft)
Vitamin D Supplementation to Prevent Cancer, CVD, Fractures, and Falls. Grade D recommendation against in community-dwelling adults ≥60.
Lerchbaum et al. (2017)N=98
Vitamin D and testosterone in healthy men: a randomized controlled trial. JCEM. Median TT change = +0.5 nmol/L, p=0.497. No significant effect on total testosterone.

Verdict Score

How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.

79 Mixed evidence
80–100Strong evidence
60–79Mixed but supportive ◀
40–59Uncertain
0–39Weak support

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score
62/100 Situational ROI Trust grade B
Conditional - test your blood first. Essential if you are deficient or 75+, close to pointless if you are already replete.
Time
Low
Money
Low
Effort
Low
Risk
Low
Why this score
Why it didn’t score higher
Best for
Lower ROI if
Minimum effective dose
600-800 IU/day of D3 for maintenance, taken with a fat-containing meal. For confirmed deficiency: 50,000 IU/week for 8 weeks (supervised), then 1,500-2,000 IU/day. Co-supplement magnesium ~300-420 mg/day if dosing above 1,000 IU. No benefit to pushing serum above 50 ng/mL.
Track this

Get the complete dosing protocol

Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.

Get the protocol

Related free research

Supplements
Plant Sterols & Stanols — The Verdict
 Supplements
Exogenous Ketones — The Verdict
 Supplements
Serrapeptase — Does the Silkworm Enzyme Actually Work?

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts